Don't expect material headwinds to earnings from increasing inflationary pressure, says Damien Conover on Johnson & Johnson (JNJ). He and Lee Bohl recap JNJ earnings. They discuss how JNJ's earnings came in better-than-expected. They also note that JNJ's 3Q worldwide pharmaceutical sales came in at $13.21B. Lee also says that JNJ spends heavily on R&D and most of M&A spending goes toward acquiring companies with promising pipeline drugs. Tune in to find out more about the stock market today.
The Watch List
19 Oct 2022
SHARE
Morning Trade Live
18 Oct 2023
Trading 360
20 Jul 2023
Morning Trade Live
18 Aug 2023
Trading 360
01 Aug 2023
Morning Trade Live
16 Oct 2023
Current show
Mon—Fri at 10:00 am — 11:00 am
Trading 360